China: Telitacicept significantly reduced proteinuria in patients with IgA nephropathy , while maintaining an acceptable safety profile comparable to that of standard treatments, offering a potential new therapeutic option, suggests a recent study. The study published in BMC Nephrology b y Hui Li and colleagues from the Department of Nephrology, Xin Hua Hospital, affiliated with Shanghai Jiao Tong University School of Medicine, evaluated the real-world effectiveness and safety of telitacicept in individuals with IgA nephropathy (IgAN). The research aimed to provide practical evidence regarding the clinical benefits of this dual B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL) inhibitor in managing IgAN. The retrospective, single-center study included

See Full Page